International Biotechnology Trust PLC - London-based investment trust managed by SV Health Managers LLP - Says Pfizer Inc’s acquisition of its investee Biohaven Pharmaceutical Holding Co Ltd has boosted net asset value by 3.6%. Pfizer on Tuesday announced the acquisition of Biohaven for $148.50 per share, at a 74% premium to the price of Biohaven before the announcement. IBT on Tuesday owned 182,000 shares in Biohaven, which constituted around 5.2% of its NAV.

Current stock price: 593.00 pence

12-month change: down 14%

Copyright 2022 Alliance News Limited. All Rights Reserved.